David Morash - Neumedicines
Protein therapeutics development company Neumedicines has appointed David Morash to its newly created role of Chief Financial Officer and given him a space on the Board of Directors.
According to Dr. Lena Basile, President and CEO of Neumedicines, the ex-CFO of ISE Corporation “joins Neumedicines at an important time in our company’s development as we make preparations to initiate clinical testing with HemaMax™ (rHuIL-12) in two cancer indications.”